Insurance Claim Denial Management
Prepared: February 20, 2026
Data vintage: Primarily 2023-2025 sources (from analyst training data; live web verification was unavailable)
Caveat: WebSearch and WebFetch tools were blocked during this session. All figures below are drawn from the analyst's training corpus (cut-off May 2025) and cite the original publication sources. Numbers should be independently verified before use in investment memos.
Author: Rigid Body Dynamics
1. PROBLEM MARKET SIZE
Revenue at Risk from Claim Denials
| Metric | Value | Source |
|---|
| Total US hospital revenue billed to insurers (2024) | ~$1.5 trillion | AHA Annual Survey / CMS NHE data |
| Initial denial rate (industry average) | 10-15% of all claims; up to 20-25% at some systems | HFMA 2023 "Denial Benchmarking" report; Experian Health 2024 survey |
| Revenue initially denied | 150B−225B annually | Derived from above |
| Net write-off from denials (after appeals) | ~1.5-3% of net patient revenue | HFMA; Crowe RCA benchmarking |
| Estimated annual write-offs from denials | 20B−45B | Derived; aligns with KFF and Advisory Board estimates |
Cost Hospitals Spend on Denial Management
| Metric | Value | Source |
|---|
| Average cost to rework/appeal a single denied claim | 25−118 per claim (varies by complexity) | AAPC 2023; Change Healthcare 2024 Revenue Cycle Index |
| Estimated total industry spend on denial management (staff, appeals, outsourcing, write-offs combined) | 19.7B−25B+ | Becker's Hospital Review 2023; derived from FTE and outsourcing data |
| Average hospital employs dedicated denial FTEs | 15-50 FTEs per mid-large hospital system | HFMA workforce surveys |
| Avg fully loaded cost per denial management FTE | 55,000−75,000/year | Bureau of Labor Statistics; Becker's |
Bottom line: Denials put 150B−225Bofhospitalrevenueatriskannually.Hospitalscollectivelyspend20B+ fighting them, and still write off $20B-45B.
2. CURRENT SPEND TO MANAGE
Revenue Cycle Management (RCM) Software Market
| Metric | Value | Source |
|---|
| 2023 market size | 154B−160B (includes services + software) | Grand View Research 2024; Verified Market Research |
| 2024 estimated | ~$176B | Grand View Research |
| 2030 forecast | 329B−398B | Grand View Research; Fortune Business Insights |
| CAGR (2024-2030) | 10.3% - 11.5% | Multiple analyst firms |
Note: The broader RCM market includes outsourced services, not just software. The software-only segment is a subset (~$20-25B in 2024).
Denial Management Software (Sub-Segment)
| Metric | Value | Source |
|---|
| 2023 estimated market size | 4.5B−5.5B | Derived from Grand View Research RCM segmentation |
| CAGR | 12-14% | Market Research Future; Allied Market Research |
| 2030 forecast | 10B−13B | Projected |
Medical Billing Outsourcing Market
| Metric | Value | Source |
|---|
| 2023 market size | 13.5B−14.8B | Polaris Market Research; Grand View Research |
| CAGR (2024-2030) | 10.1% - 12.3% | Multiple sources |
| 2030 forecast | 26B−30B | Projected |
3. COST OF INACTION
| Metric | Value | Source |
|---|
| % of denied claims never appealed | 50-65% | Premier Inc. 2023 analysis; Advisory Board 2024 |
| Reason most not appealed | Cost-to-appeal exceeds claim value, or staff bandwidth exhausted | HFMA |
| Average cost to work one denial | 25(simple)to118 (complex/clinical) | Change Healthcare 2024 Index; AAPC |
| Average cost to file a formal appeal | 48−118 per claim | AAPC; Experian Health |
| Revenue lost from uncontested denials annually | 10B−27B (est. 50-65% of 20B−45B write-off pool) | Derived |
| Appeal overturn/success rate (when pursued) | 50-70% | MGMA 2023; HFMA |
Key insight: More than half of denied claims are never contested, yet when hospitals do appeal, they win 50-70% of the time. This represents a massive recoverable revenue pool that is abandoned due to operational capacity constraints.
4. VOLUME FREQUENCY
| Metric | Value | Source |
|---|
| Total medical claims submitted/year (US, all payers) | ~6 billion claims (professional + institutional combined) | CAQH 2024 Index; CMS data |
| Hospital/facility claims specifically | ~1.2 - 1.5 billion | AHA; derived from CMS |
| Initial denial rate (all claims) | 10-15% | Experian Health 2024; Change Healthcare |
| Initial denial rate (hospital inpatient) | 15-25% (higher complexity) | HFMA 2023; KFF |
| Claims denied on first submission annually | ~200-350 million hospital claims | Derived |
| Prior authorization denial rate (Medicare Advantage) | 13-18% of prior auth requests | KFF 2024 Medicare Advantage report; OIG |
| Appeals filed as % of denials | 35-50% | Premier; Advisory Board |
| Estimated appeals filed annually (hospital) | ~70-175 million | Derived |
| Average time to resolve a denial (rework + appeal) | 30-60 days (simple); 90-180+ days (complex/multi-level appeal) | HFMA; Waystar benchmarking data |
| Average days in A/R for denied claims | 45-90 days beyond initial billing cycle | MGMA benchmarks |
5. WHY STILL UNSOLVED
Despite billions invested in RCM technology, denial rates have risen ~23% over the past decade (Change Healthcare Index, 2024). Key structural reasons:
5.1 Payer Algorithm Changes (Moving Target Problem)
- Insurers continuously update clinical criteria, coverage policies, and prior auth rules
- Medicare Advantage plans use proprietary AI/ML algorithms to auto-adjudicate (and auto-deny) claims
- OIG found MA plans denied 13-18% of prior auths, many of which met Medicare coverage criteria
- Payer rule changes outpace provider RCM software update cycles
5.2 Coding Complexity Explosion
- ICD-10 has ~72,000 diagnosis codes vs. ~14,000 in ICD-9
- CPT code updates annually (300+ changes/year)
- Modifier requirements increasingly complex
- Clinical documentation must precisely match coding requirements
5.3 Staff Turnover and Workforce Crisis
- Medical coder/biller turnover: 25-40% annually (AAPC 2024 salary survey)
- Average time to train a denial management specialist: 6-12 months
- Post-COVID burnout accelerated departures from revenue cycle roles
- Experienced coders retiring faster than replacements entering
5.4 Data Fragmentation
- Average hospital uses 15+ disparate systems (EHR, PM, clearinghouse, payer portals)
- Lack of real-time eligibility/benefit verification at point of care
- Clinical documentation lives in EHR; billing data in PM system; payer rules on external portals
- No single source of truth connecting clinical, financial, and payer data
5.5 Misaligned Incentives
- Payers benefit financially from denials (float, write-offs)
- Payers face minimal penalties for inappropriate denials
- Provider appeals process is deliberately cumbersome
- CMS has been slow to enforce payer accountability
5.6 Legacy RCM Software Limitations
- Most RCM platforms are rules-based, not predictive
- Retrospective denial tracking vs. prospective denial prevention
- Batch processing vs. real-time intervention
- Limited NLP/AI capability for clinical documentation analysis
6. WILLINGNESS TO PAY SIGNALS
What Hospitals Pay Today
| Category | Annual Spend | Source |
|---|
| In-house RCM team (avg mid-size hospital, ~50 FTEs) | 3M−5M/year | BLS; HFMA |
| In-house RCM team (large health system, 200+ FTEs) | 12M−20M/year | Becker's |
| Outsourced RCM services (% of collections model) | 4-8% of net patient revenue | HFMA; vendor benchmarks |
| Outsourced RCM for a $500M revenue hospital | 20M−40M/year | Derived |
| Denial management software (per-provider pricing) | 50K−500K/year per facility | Vendor pricing; KLAS |
| AI-powered denial prevention platforms | 200K−1M+/year per health system | KLAS 2024; vendor data |
VC/PE Investment Activity (2023-2025)
| Company / Deal | Amount | Date | Investor(s) |
|---|
| Waystar IPO | ~$968M raised (IPO) | June 2024 | Public markets (backed by EQT, CPPIB) |
| Akasa (AI for RCM) | $60M Series B | 2023 | Andreessen Horowitz (a16z) |
| AKASA total raised | $120M+ | Through 2024 | a16z, BOND, others |
| Olive AI (RCM automation) | Wound down; assets acquired by Waystar, others | 2023 | Previously raised $900M+ |
| Infinx (AI prior auth) | $75M+ total | 2023-2024 | Multiple PE/VC |
| Apixio/ClaimLogiq (AI denials) | Acquired by New Mountain Capital | 2023 | PE |
| R1 RCM | Acquired by TowerBrook/CD&R for $8.9B | 2024 | PE |
| Ensemble Health Partners | Acquired by Bon Secours for strategic partnership | 2024 | Health system |
| Nividous / Autonomize AI | $15-30M rounds for RCM AI startups | 2023-2024 | Various VC |
| Medallion (credentialing/RCM adjacent) | $44M Series C | 2024 | Various |
Signal strength: The R1 RCM acquisition at 8.9BandWaystarIPOat 3.7B market cap on listing day demonstrate massive PE/public market appetite. Multiple AI-native startups raising 50M−120M rounds specifically for denial management signals strong WTP for next-gen solutions.
7. MARKET GROWTH RATE
| Segment | 2024 Size (Est.) | 2030 Forecast | CAGR |
|---|
| Total RCM Market (services + software) | $176B | 329B−398B | 10.3% - 11.5% |
| RCM Software Only | 20B−25B | 48B−55B | 11% - 13% |
| Denial Management Software | 5B−6B | 10B−13B | 12% - 14% |
| Medical Billing Outsourcing | 14B−15B | 26B−30B | 10% - 12% |
| AI in Healthcare RCM (sub-segment) | 2B−3B | 8B−12B | 20% - 25% |
Key growth drivers:
- Regulatory complexity increasing (No Surprises Act, prior auth reform)
- Labor shortages forcing automation adoption
- Medicare Advantage enrollment growth (more complex payer mix)
- AI/ML maturation enabling predictive denial prevention
- CMS interoperability mandates creating data availability
8. KEY PLAYERS TODAY
Major RCM / Denial Management Companies
| Company | Est. Revenue (2024) | Segment Focus | Notes |
|---|
| Waystar | ~770M−850M | RCM software, clearinghouse, denial mgmt | IPO June 2024; EQT-backed; acquired Olive AI assets |
| R1 RCM | ~$2.2B | End-to-end RCM outsourcing + tech | Acquired by TowerBrook/CD&R for $8.9B (2024) |
| Cotiviti (Verscend) | ~1.0B−1.2B | Payment accuracy, analytics, risk adjustment | Owned by Veritas Capital; serves payer + provider |
| Change Healthcare (Optum) | ~$3.5B+ (segment) | Clearinghouse, RCM, payment integrity | Part of UnitedHealth/Optum after $7.8B acquisition (2022); major cyberattack Feb 2024 |
| nThrive (now part of R1 RCM) | Folded into R1 | Coding, CDI, denial management | Merged with R1 RCM |
| Omega Healthcare | ~500M−700M | RCM outsourcing (India-based operations) | Large offshore BPO for RCM |
| Ensemble Health Partners | ~$1.0B+ | End-to-end RCM outsourcing | Strategic deals with health systems |
| GeBBS Healthcare | ~200M−300M | RCM outsourcing, coding | India-based |
| AGS Health | ~150M−250M | RCM outsourcing, denial management | India-based |
| Experian Health | ~500M−700M (health segment) | Eligibility, claims, patient access | Part of Experian plc |
AI-Native Disruptors
| Company | Funding / Stage | Focus |
|---|
| AKASA | $120M+ raised | AI-powered RCM automation |
| Infinx | $75M+ raised | AI prior authorization |
| Apixio / ClaimLogiq | PE-backed (New Mountain) | AI-powered denial management |
| Adonis | ~$20M+ raised | AI denial prevention for physician groups |
| Rhyme Health | Early stage | AI denial appeals automation |
| Valer | Early stage | Denial prediction and prevention |
9. KEY SOURCES
All sources referenced in this report. Note: URLs are provided as best-known links; some may require subscription access.
Industry Associations and Government
- HFMA (Healthcare Financial Management Association) - Denial benchmarking reports and workforce surveys
- KFF (Kaiser Family Foundation) - Medicare Advantage denial data
- CMS National Health Expenditure Data - Total healthcare spending
- OIG (HHS Office of Inspector General) - MA denial investigations
- AHA (American Hospital Association) - Hospital statistics
- CAQH Index - Claims volume and automation data
Market Research Firms
- Grand View Research - RCM market analysis
- Fortune Business Insights - RCM market forecast
- Polaris Market Research - Medical billing outsourcing
- Allied Market Research - Denial management market
- Market Research Future - Healthcare RCM
Industry Publications and Data
- Change Healthcare / Optum Revenue Cycle Index - Denial rate trends and cost-to-appeal data
- Experian Health - State of Claims survey (2024)
- Becker's Hospital Review - RCM workforce and spending
- Fierce Healthcare - Denial rate trends
- KLAS Research - RCM software vendor ratings
- Advisory Board (Optum) - Denial management analytics
- Premier Inc. - Denial analytics and benchmarking
- AAPC - Coding workforce and salary data
- MGMA - Practice management benchmarks
Deal / Investment Sources
- Waystar S-1 / IPO Filing - SEC Edgar
- R1 RCM Take-Private - Press coverage
- AKASA Funding - Crunchbase / press releases
EXECUTIVE SUMMARY
The US insurance claim denial management problem represents one of the largest inefficiencies in healthcare:
- 150B−225B in hospital revenue is initially denied annually
- 20B−45B is permanently written off, with 50-65% of denials never even appealed
- When hospitals do appeal, they win 50-70% of the time -- revealing a massive recoverable revenue pool abandoned due to operational constraints
- Hospitals spend $20B+ annually on denial management through a combination of in-house staff, outsourced services, and technology
- The RCM market is growing at 10-13% CAGR with AI-specific sub-segments growing at 20-25%
- PE/VC conviction is high: R1 RCM acquired for 8.9B∗∗,∗∗WaystarIPOat 3.7B, and $200M+ deployed into AI-native denial management startups in 2023-2024
The problem persists because it is structurally adversarial (payers benefit from denials), operationally complex (72,000 ICD-10 codes, constantly changing payer rules), and plagued by workforce challenges (25-40% coder turnover). Legacy RCM tools are rules-based and retrospective. The market is ripe for AI-native solutions that can predict denials before submission, auto-generate appeals, and adapt in real-time to payer algorithm changes.
Largest opportunity vector: Converting the 50-65% of denials that are currently abandoned into appealed and recovered revenue using AI-powered automation. At a 60% appeal success rate, this represents 6B−16B in recoverable revenue annually -- a value proposition that can support premium SaaS pricing.